

# Kenneth N Olivier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9700158/publications.pdf>

Version: 2024-02-01

65  
papers

9,960  
citations

87888

38  
h-index

110387

64  
g-index

65  
all docs

65  
docs citations

65  
times ranked

9122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i> . <i>Science</i> , 2014, 345, 1623-1627.	12.6	745
2	GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. <i>Blood</i> , 2014, 123, 809-821.	1.4	599
3	Nontuberculous Mycobacteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 828-834.	5.6	595
4	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110 $\beta$ result in T cell senescence and human immunodeficiency. <i>Nature Immunology</i> , 2014, 15, 88-97.	14.5	575
5	Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare Beneficiaries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 881-886.	5.6	547
6	Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 970-976.	5.6	487
7	Adult-Onset Immunodeficiency in Thailand and Taiwan. <i>New England Journal of Medicine</i> , 2012, 367, 725-734.	27.0	431
8	The association between sterilizing activity and drug distribution into tuberculosis lesions. <i>Nature Medicine</i> , 2015, 21, 1223-1227.	30.7	387
9	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	5.8	367
10	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	5.8	357
11	Pulmonary Nontuberculous Mycobacterial Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1066-1074.	5.6	356
12	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i> , 2016, 71, i1-i22.	5.6	348
13	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	6.7	336
14	Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. <i>Blood</i> , 2010, 115, 1519-1529.	1.4	299
15	Adult Patients With Bronchiectasis. <i>Chest</i> , 2017, 151, 982-992.	0.8	282
16	Respiratory Outbreak of <i>Mycobacterium abscessus</i> Subspecies <i>massiliense</i> in a Lung Transplant and Cystic Fibrosis Center. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 231-232.	5.6	277
17	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. <i>Thorax</i> , 2016, 71, 88-90.	5.6	274
18	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. <i>JCI Insight</i> , 2016, 1, .	5.0	219

#	ARTICLE	IF	CITATIONS
19	Nontuberculous Mycobacteria. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 835-840.	5.6	214
20	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 814-823.	5.6	212
21	Cohort Study of Molecular Identification and Typing of <i>Mycobacterium abscessus</i> , <i>Mycobacterium massiliense</i> , and <i>Mycobacterium bolletii</i> . Journal of Clinical Microbiology, 2009, 47, 1985-1995.	3.9	210
22	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal, 2018, 51, 1800170.	6.7	159
23	Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. Annals of the American Thoracic Society, 2014, 11, 30-35.	3.2	156
24	Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 618-628.	5.6	136
25	Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood, 2011, 118, 3715-3720.	1.4	131
26	Epidemiology of Nontuberculous Mycobacterial Infections and Associated Chronic Macrolide Use among Persons with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 807-812.	5.6	123
27	Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010–2014. Annals of the American Thoracic Society, 2018, 15, 817-826.	3.2	113
28	High-level Relatedness among <i>Mycobacterium abscessus</i> subsp. <i>massiliense</i> Strains from Widely Separated Outbreaks. Emerging Infectious Diseases, 2014, 20, 364-371.	4.3	108
29	Familial Clustering of Pulmonary Nontuberculous Mycobacterial Disease. Chest, 2010, 137, 629-634.	0.8	74
30	Abnormal Nasal Nitric Oxide Production, Ciliary Beat Frequency, and Toll-like Receptor Response in Pulmonary Nontuberculous Mycobacterial Disease Epithelium. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1374-1381.	5.6	70
31	Environmental Risks for Nontuberculous Mycobacteria. Individual Exposures and Climatic Factors in the Cystic Fibrosis Population. Annals of the American Thoracic Society, 2014, 11, 1032-1038.	3.2	67
32	Semiquantitative Culture Analysis during Therapy for <i>Mycobacterium avium</i> Complex Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 754-760.	5.6	67
33	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. Annals of the American Thoracic Society, 2016, 13, S379-S384.	3.2	58
34	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	5.6	53
35	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	12.4	52
36	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infectious Diseases, The, 2022, 22, e178-e190.	9.1	51

#	ARTICLE	IF	CITATIONS
37	Clonal Diversification and Changes in Lipid Traits and Colony Morphology in <i>Mycobacterium abscessus</i> Clinical Isolates. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3438-3447.	3.9	48
38	Lung Manifestations in an Autopsy-Based Series of Pulmonary or Disseminated Nontuberculous Mycobacterial Disease. <i>Chest</i> , 2012, 141, 1203-1209.	0.8	43
39	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36
40	Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 617-618.	2.9	31
41	MPEG1/perforin-2 mutations in human pulmonary nontuberculous mycobacterial infections. <i>JCI Insight</i> , 2017, 2, .	5.0	30
42	Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, <i>TTK</i> , for Pulmonary Nontuberculous Mycobacterial Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1599-1604.	5.6	28
43	Pulmonary Manifestations of GATA2 Deficiency. <i>Chest</i> , 2021, 160, 1350-1359.	0.8	21
44	A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase <sup>®</sup> ) in adult subjects with well-controlled asthma. <i>BMC Infectious Diseases</i> , 2015, 16, 54.	2.9	18
45	Antibacterial activity of high-dose nitric oxide against pulmonary <i>Mycobacterium abscessus</i> disease. <i>Access Microbiology</i> , 2020, 2, acmi000154.	0.5	18
46	CFTR modulator use and risk of nontuberculous mycobacteria positivity in cystic fibrosis, 2011–2018. <i>ERJ Open Research</i> , 2022, 8, 00724-2021.	2.6	18
47	Adaptability and Persistence of the Emerging Pathogen <i>Bordetella petrii</i> . <i>PLoS ONE</i> , 2013, 8, e65102.	2.5	17
48	Genome-wide association study in patients with pulmonary <i>Mycobacterium avium</i> complex disease. <i>European Respiratory Journal</i> , 2021, 58, 1902269.	6.7	16
49	Pulmonary Manifestations of the Autoimmune Lymphoproliferative Syndrome. A Retrospective Study of a Unique Patient Cohort. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1279-1288.	3.2	13
50	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0221221.	3.2	13
51	Mediastinal and Disseminated <i>Mycobacterium kansasii</i> Disease in GATA2 Deficiency. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2169-2173.	3.2	11
52	Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design. <i>PLoS ONE</i> , 2021, 16, e0261628.	2.5	10
53	Lady Windermere Dissected: More Form Than Fastidious. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1674-1676.	3.2	8
54	Survival of pathogenic <i>Mycobacterium abscessus</i> subsp. <i>massiliense</i> in <i>Acanthamoeba castellanii</i> . <i>Research in Microbiology</i> , 2018, 169, 56-60.	2.1	7

#	ARTICLE	IF	CITATIONS
55	Antimicrobial peptides against drug resistant <i>Mycobacterium abscessus</i> . <i>Research in Microbiology</i> , 2020, 171, 211-214.	2.1	7
56	ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1473-1475.	5.6	6
57	Amikacin exposure and susceptibility of macrolide-resistant <i>Mycobacterium abscessus</i> . <i>ERJ Open Research</i> , 2019, 5, 00154-2018.	2.6	6
58	Beyond Marfan: the clinical impact of bronchiectasis and non-tuberculous mycobacteria in connective tissue diseases. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1409-1409.	1.2	5
59	<i>Pneumocystis</i> Colonization in Asthmatic Patients not Receiving Oral Corticosteroid Therapy. <i>Journal of Investigative Medicine</i> , 2017, 65, 800-802.	1.6	5
60	Impact of periprocedural subcutaneous parathyroid hormone on control of hypocalcaemia in APSâ€1/APECED patients undergoing invasive procedures. <i>Clinical Endocrinology</i> , 2021, 94, 377-383.	2.4	3
61	Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2020, 7, 390-403.	0.7	3
62	Bronchiectasis and connective tissue diseases. <i>Current Pulmonology Reports</i> , 2016, 5, 169-176.	1.3	1
63	Fatal autoimmune pneumonitis requiring bilobectomy and omental flap repair in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101476.	0.4	1
64	Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI). , 2015, , .		1
65	HALT-ing Nontuberculous Mycobacteria in CF Centers. Is There Something in The Water?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	5.6	1